Fetal and Maternal Placental and Nonplacental Clearances of Metoclopramide in Chronically Instrumented Pregnant Sheep

doi:10.1002/jps.2600791204

Journal of Pharmaceutical Sciences

Volume 79, Issue 12, December 1990, Pages 1056-1061

https://doi.org/10.1002/jps.2600791204 Get rights and content

Abstract

The placental and nonplacental clearances of metoclopramide were studied in nine chronically instrumented, near-term pregnant sheep using a two-compartment open model. Metoclopramide was administered to the ewe and fetus on separate occasions as an initial iv bolus loading dose followed by a constant-rate infusion, with steady-state maternal and fetal plasma concentrations being obtained by 45 min. Following the maternal infusions, metoclopramide reached average steady-state concentrations of 50.0 ± 20.2 ng/mL in the ewe and 27.1 ± 8.6 ng/mL in the fetus, with a mean fetal-to-maternal concentration ratio of 0.57 ± 0.14. The ability of the fetus to eliminate metoclopramide by nonplacental routes appears to be responsible for this ratio being less than unity, rather than differential protein binding and ion-trapping effects. Mean steady-state concentrations were 13.8 ± 4.5 and 253.7 ± 92.1 ng/mL in the ewe and fetus, respectively, after fetal drug administration. Metoclopramide was bound significantly less to fetal (39.5 ± 8.9%) than to maternal (49.5 ± 7.9%) plasma proteins, with values similar to that reported for humans (≈ 40%). Clearance of metoclopramide across the placenta from the fetus to the ewe (6.2 ± 2.4 L/h/kg) was significantly greater than that in the reverse direction (4.3 ± 1.3 L/h/kg) and accounted for ≈ 80% of total fetal drug elimination. This may be explained by the higher percentage of fetal cardiac output to the placenta and the flow-limited transfer of this compound. Nonplacental routes (e.g., renal, hepatic) were responsible for only ≈ 20% of total fetal drug elimination (7.9 ± 2.9 L/h/kg), but, they comprised the major source (≈ 95%) of total maternal drug clearance (2.9 ± 0.4 L/h/kg). Neither maternal nor fetal drug administration resulted in any consistent or significant cardiorespiratory or behavioral effects in the fetal lamb, even though very high concentrations were obtained in fetal plasma following fetal dosing.

References (38)

K.W. Riggs et al.
J. Pharm. Sci.
(1988)
K.W. Riggs et al.
J. Chromtogr.
(1983)
G.W. Mihaly et al.
Pharm. Sci.
(1982)
B. Krauer et al.
Pharmacol. Ther.
(1980)
M.C. Bogaert et al.
Eur. J. Obstet. Gynec. Reprod. Biol.
(1983)
G.R. Gourley et al.
Pediatrics
(1982)
T.C. Kwong
Clin. Chim. Acta
(1985)
M.D. Hill et al.
Pharm. Sci.
(1986)
H.H. Szeto et al.
Life Sci.
(1982)
K.W. Riggs et al.
Am. J. Obst. Gynecol.
(1987)

H.H. Szeto et al.

Am. J. Obstet. Gynecol.

(1982)

R. Albibi et al.

Ann. Int. Med.

(1983)

R.A. Harrington et al.

Drugs

(1983)

P.V. Desmond et al.

Med. J. Australia

(1986)

D.R. Solanki et al.

Anesth. Analg.

(1984)

M. Bylsma-Howell

Can. Anaesth. Soc. J.

(1983)

S.E. Cohen et al.

Anesthesiology

(1984)

K.W. Riggs

M.Sc. Thesis

(1982)

P. Arvela et al.

Eur. J. Clin. Pharmacol.

(1983)

Cited by (18)

Key Points in Fetal Drug Distribution
2017, Fetal and Neonatal Physiology, 2-Volume Set
Simple HPLC method for determination of rosiglitazone in sheep plasma and amniotic fluid and its application in a pregnant sheep model
2011, Journal of Pharmaceutical and Biomedical Analysis
Citation Excerpt :
Nevertheless, drugs can cross the placenta and pose a risk to the developing fetus. In the absence of other clearance mechanisms, the placenta plays a significant role in fetal drug clearance, and indeed many drugs, including labetalol [15], metoclopramide [16] and diphenhydramine [17], are preferentially transported from the fetus to the maternal circulation. The model used in this study is unusual in that the drug is dosed directly to the fetus, rather than to the ewe, with the intention of allowing the drug to accumulate and hence exert a sustained effect on fetal PPAR-γ receptors.
This paper describes the development of a sensitive high performance liquid chromatography (HPLC) method for quantification of rosiglitazone in sheep plasma and amniotic fluid. Samples were prepared by liquid–liquid extraction using tert-butyl methyl ether, and rosiglitazone was quantitated by HPLC using a C18 column and fluorescence detector with an excitation wavelength of 247 nm and emission wavelength of 367 nm. The mobile phase consisted of ammonium acetate (10 mM, pH 5.2) and acetonitrile (56.5:43.5, v/v) with a flow rate of 1 ml/min. Ketoconazole was used as the internal standard (IS).
The plasma calibration curve was linear over the range of 2.5–250 ng/ml (mean r² = 0.9940 ± 0.0024; n = 6) with accuracy of 99.4–102.8% over the calibration range. The intra-day and inter-day coefficient of variation (%CV, percent coefficient of variation) were in the range of 0.01–8.68% in sheep plasma. Similar performance was achieved for amniotic fluid. The described method was successfully applied to quantitate rosiglitazone concentrations in the pregnant ewe and her fetus.
Drug Distribution in Fetal Life
2011, Fetal and Neonatal Physiology E-Book, Fourth Edition
Drug Distribution in Fetal Life
2003, Fetal and Neonatal Physiology: Third Edition
Fetal hepatic drug elimination
1999, Pharmacology and Therapeutics
The majority of studies of fetal hepatic elimination have concentrated on the expression and activity of the metabolizing enzymes, but the unique physiologic milieu of the fetal liver should also be considered. The basic structure of the liver is formed by the end of the first trimester. The fetal hepatic circulation differs substantially from that of the adult in that there is an extra input vessel, the umbilical vein, and there is shunting of 30–70% of hepatic blood flow via the ductus venosus. The left and right lobes of the fetal liver seem to function independently with respect to a variety of biochemical parameters, due at least in part to the lower oxygen supply to the right lobe. The zonation of drug-metabolizing enzymes along the hepatic acinus, which is prominent in the adult liver, is absent in the fetal liver. Unlike rodent species, the human fetal liver has a significant capacity for drug metabolism. Of the oxidative enzymes, CYP3A7 accounts for up to 50% of total fetal hepatic cytochrome P450 content. Expression of this enzyme decreases dramatically after birth. CYP1A1 and CYP2D6 have also been detected in human fetal liver, but whether CYP2E1 is expressed remains controversial. Several other cytochrome P450s have been identified and await characterization. Fetal hepatic drug conjugation may prolong fetal exposure to the metabolites produced, which, being more water soluble, do not readily cross the placenta back to the mother and, if excreted in fetal urine, can be recycled in the fetus via amniotic fluid and fetal swallowing. Limited activity of glucuronidation enzymes has been demonstrated in human fetal liver in contrast to the activity of sulfation enzymes, which is significant. Limited in vivo studies in fetal sheep have demonstrated significant fetal hepatic drug elimination, and this has been confirmed in studies of the isolated perfused fetal sheep liver. Our understanding of fetal hepatic elimination processes has advanced steadily over the years. Future developments, however, should consider more fully the influence of the unique physiological milieu of the fetal liver, in addition to the expression and activity of drug metabolizing enzymes.
Pharmacology of drug transfer across the placenta
1998, Obstetrics and Gynecology Clinics of North America
The fetus is exposed to the environment through interactions with the mother. The unique nature of the fetal habitat and the adaptations of the fetus to the intrauterine environment require that special attention be paid to fetal pharmacology. This review provides a basic framework for the clinician to evaluate fetal drug exposure and the likely consequences of such exposure using dose-response principles. The specific areas focused on are (1) the general mechanisms by which drugs administered to the mother exert their effect on the fetus, (2) how fetal drug exposure relates to maternal drug concentration, (3) placental permeability and mechanisms of placental transfer, and (4) the role of the fetus in determining fetal concentrations.

View all citing articles on Scopus

View full text

ArticlesFetal and Maternal Placental and Nonplacental Clearances of Metoclopramide in Chronically Instrumented Pregnant Sheep

Abstract

J. Chromtogr.

Pharm. Sci.

Pharmacol. Ther.

Eur. J. Obstet. Gynec. Reprod. Biol.

Pediatrics

Clin. Chim. Acta

Pharm. Sci.

Life Sci.

Am. J. Obst. Gynecol.

Am. J. Obstet. Gynecol.

Ann. Int. Med.

Drugs

Med. J. Australia

Anesth. Analg.

Can. Anaesth. Soc. J.

Anesthesiology

M.Sc. Thesis

Eur. J. Clin. Pharmacol.

Articles
Fetal and Maternal Placental and Nonplacental Clearances of Metoclopramide in Chronically Instrumented Pregnant Sheep